The biotechnology industry has been at the forefront of the fight against the Covid-19 pandemic by creating and using various tools, such as vaccines, antivirals, diagnostic tests, and remote health monitoring. The biotech market is cost-intensive and has a much higher gestation period; many solo investors and venture capital firms are yet to allocate their resources in this field. The rising demand for nucleic acid and protein sequencing, initiatives from private and government organizations, advancements in technologies like Crispr Cas9 and Car T cell therapy, and drug discovery are all growth factors for the biotech market.
Though cancer treatment has advanced with targeted therapy and immunotherapy, there is still a massive gap as none of them addresses Metastasis. Mestastop is one such company that aims to provide a solution for stopping Metastasis with their unique proprietary platforms, METASSAY, METSCAN, and METVivo.
While immense strides have been made in understanding tumor biology and developing effective treatments that have substantially improved the prognosis of cancer patients, Metastasis remains the primary cause of cancer-related death. It’s hard to imagine waking up every morning, seeing your loved ones, and then
remembering there is not much time left. It is dying every moment, not only for the patient but for their loved ones. With an enriching journey, Mestastop started with hardcore research in Metastasis and emphasized the unexplored part of metastasis biology, deciphering the key rate-limiting critical steps. With the intent to address the pain point of such patients and delay, if not prevent, Metastasis, the company has built custom platforms and now employing them to find new treatments. “Mestastop provides a great opportunity at finding solutions to the unmet medical needs in cancer care", speaks Dr. Debabani Roy Chowdhury, Co-Founder, Mestastop.
Unraveling the Complexity of Metastasis
Mestastop has created three proprietary platforms, both in vitro and in vivo, along with patient tumor translational validation, to unravel the complexity of metastasis drug discovery and early predictive diagnostics. These platforms are ready to be used for novel drug discovery, drug repurposing, and profiling current anti-cancer leads or candidates for their anti-metastatic effect. The company has differentiated between the growing tumorigenic and moving metastatic cells, identifying critical patterns that are translationally significant. Mestastop brings deep expertise in biology of cancer metastasis to the table. ”Being industry experts, Mestastop has a proven track record of offering flexible business models with cost-effective and accelerated R&D timescales", speaks Manoj Pandre, Senior Scientist, Mestastop.
Mestastop provides a great opportunity at finding solutions to the unmet medical needs in cancer care
Mestastop has a team of around eight people on the bench with over 80+ years of cumulative experience, half of whom are PhDs. Its Senior Leadership team has 70+ years of experience in significant pharma drug discovery, and the medical oncology advisors are India’s best, with a cumulative experience of 140+ years. All these experiences focus on correctly identifying the problem and then working on the most probable and feasible solutions. The company has filed two international patents already and is willing to support pharma and biotech with its technology.
Mestastop aims to be as quick as possible in translating its unique platforms to meaningful solutions for patients and are looking for multiple active collaborations. Its next mission is to employ the proprietary platforms to address novel drug discovery and drug repurposing around Metastasis. With its hard work and passion for bringing cures to patients, Mestastop is positioned to be a game-changer within the next decade.
.jpg "Overcoming the Hurdles of Scaling a Startup")
